Talbot Alexis
@DrAlexisTalbot
Followers
835
Following
5K
Media
209
Statuses
3K
Assistant Professor in Immunology Paris #myeloma #MGCS #CART @aphp @HopSaintLouis @institut_IRSL @Univ_Paris @HIPI_inserm @UCSF https://t.co/Hfou5jiToD
San Francisco, California, US
Joined June 2012
Disparition du scientifique et immunologiste israélien Zelig Eshhar, pionnier de l’immunothérapie et considéré comme l'un des "pères" de la technologie des cellules CAR-T pour lutter contre les cancers, redonnant espoir à des milliers de patients dans le monde.
Save the date:. Save the date: . Zelig Eshhar Memorial Symposium | CAR-T Cells: from Vision to Revolution. Wednesday, September 2nd at The David Lopatie Conference Centre on the Weizmann Institute of Science
1
0
4
Thanks @Myeloma_Doc for highlighting our report of the first patient treated with anti-BCMA bispecific for R/R POEMS syndrome with a 20-year history in @Haematologica @APHP @HopSaintLouis @Filiere_MaRIH #POEMS #mmsm.
Myeloma Paper of the Day, July 9th, Suggested by Robert Orlowski (@Myeloma_Doc).@DrAlexisTalbot. #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma #Teclistamab #POEMSsyndrome @CancerWorldmag
0
0
3
RT @thanosdimop: Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm
https://t….
nature.com
Nature Reviews Clinical Oncology - In these Evidence-Based Guidelines, a multidisciplinary panel of experts from the European Hematology Association and the European Myeloma Network provide key...
0
28
0
RT @VincentRK: Just out! New IMS/ IMWG Definition of High Risk Myeloma. @JCO_ASCO #IMWG25. @Myeloma_Society @IMFmyeloma @NikhilMunshiMD @m….
0
117
0
RT @Mohty_EBMT: The On-Body Delivery System redefines care by putting treatment in motion, freeing patients from hospital chairs and giving….
0
10
0
RT @RahulBanerjeeMD: #ASCO25 And another one!.@JCO_ASCO: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated….
0
20
0
Just published in the @NEJM following Dr. @PerrotAurore 's presentation at #ASCO25 on behalf of the IFM group 🇫🇷 and C. Touzeau. 📢📄 MRD-driven strategy in NDMM, a major step forward for multiple myeloma research. #mmsm #MRD #NDMM #IFM.
Presented at #ASCO25: . In newly diagnosed myeloma, ASCT showed no benefit over chemotherapy in patients without postinduction measurable residual disease, and tandem ASCT was not more effective than single ASCT in those with postinduction MRD. Full MIDAS phase 3 trial results:
0
1
10
Un test simple et rapide à faire pour ceux qui veulent prendre soins de leur santé par @Institut_cancer
cancer.fr
L’Institut national du cancer sort un nouvel outil ludique et interactif : « Mon test prévention cancers ». Grâce à ce test, chacun peut identifier, dans son quotidien, les comportements à risque et...
0
0
1
RT @VPrasadMDMPH: By request.Our 2 hour ASH abstract session.@AaronGoodman33 @ManniMD1 and me and many others.We get to the abstracts aroun….
0
24
0
RT @hopitalbichat: Maladies rares, faire équipe !.Il reste des places pour la journée annuelle de la Plateforme d'expertise maladies rares….
0
5
0
RT @VincentRK: My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24.#ASH24VR. 1. Newly diagnosed transplant ineligible.….
0
121
0
RT @VincentRK: Here are my Top 5 #ASH24 @ASH_hematology myeloma abstracts. #ASH24VR . Links to the full abstract. My Top 5 are based on ne….
0
71
0
RT @ComeBommier: 🔥What's trending at #ASH24 in Marginal Zone Lymphoma (MZL)?. Here's a quick breakdown of the key highlights. On the MZL a….
0
8
0
RT @ComeBommier: Real-world data in #MZL are rare and precious. So far: 🇺🇸 @LEOcohort, 🇮🇹NF10, 🇬🇧 HMRN. Thanks to @LysaLymphoma's REALYSA,….
onlinelibrary.wiley.com
Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited representativeness, there is a need for...
0
7
0
RT @Rfonsi1: Dr. @PerrotAurore presenting MIDAS trial. Incorporates MRD testing for the various pathways. MRD adapted consolidation and mai….
0
12
0
Prochaine RCP nationale "MGCS: Gammapathie monoclonale de signification cutanée" organisée par notre centre constitutif intégré @Filiere_MaRIH avec le centre de ref AmyloseAL le 2/10/2024 à 17h, MP pour plus d'info @univ_paris_cite @HopSaintLouis @SFDermatologie @Hematologie_JLE.
0
2
1